Why the study?
Does lisinopril improve systemic extracellular degradation of collagen type I in patients with essential hypertension?
Does lisinopril improve systemic extracellular degradation of collagen type I in patients with essential hypertension?
Lisinopril normalizes depressed systemic extracellular degradation of collagen type I in patients with essential hypertension, which may help prevent organ fibrosis and left ventricular hypertrophy.
May help prevent fibrosis and LVH in hypertension; leaves open confirmation in prospective trials.
These findings suggest that systemic extracellular degradation of collagen type I is depressed in patients with essential hypertension and can be normalized by treatment with lisinopril. A depressed degradation of collagen type I may facilitate organ fibrosis in hypertensive patients, namely, in those with left ventricular hypertrophy.
No takes yet. Share an insight, caveat, or question.
Laviades et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: